Formulation for menopausal women

The present disclosure relates to novel compositions which provide improved nutritional support for premenopausal and menopausal women and/or relief from symptoms associated with menopause, as well as prophylactic effects, and methods for using same.

EXAMPLES 
 Example 1 The following formulations are used to prepare compositions for administration to premenopausal and menopausal women: 1 Component Dose Units Vitamin A (Beta Carotene) 5,000 I.U. Vitamin D 400 I.U. Vitamin E 400 I.U. Vitamin C 100 mg. Vitamin B1 20 mg. Vitamin B2 20 mg. Vitamin B6 25 mg. Vitamin B12 50 mcg. Vitamin B3 100 mg. Folic Acid 1.0 mg. Calcium Carbonate 1,200 mg. Copper 2 mg. Zinc 15 mg. Selenium 65 mcg. DHA/Linolenic/Linoleic Acid 50/25/25 mg. It would be anticipated that upon administration of the above composition, an average normal menopausal woman would be expected to have reduced incidence of nutritional deficiency and reduced menopausal-related symptoms or disorders when compared to an average normal menopausal woman following a conventional nutritional regimen. 
 Example 2 The following compositions are for administration to premenopausal women and menopausal women in accordance with the regimen indicated below: 2 Regimen Component Dose First Morning Calcium Carbonate 350 mg Tablet (orange): B Complex 55 mg Second Morning Calcium Carbonate 350 mg Tablet (white): Vitamin A 3,000 IU Vitamin C 100 IU Vitamin D 400 IU Selenium 65 mcg Zinc 15 mg Copper 2 mg Evening Tablet Calcium Carbonate 350 mg B Complex 110 mg Vitamin A 2,000 IU Folic Acid 1 mg Evening Capsule Vitamin E 400 IU DHA 50 mg Linolenic Acid 25 mg Linoleic Acid 25 mg Calcium Carbonate 150 mg It would be anticipated that upon following the above regimen, an average normal menopausal woman would be expected to have reduced incidence of nutritional deficiency and reduced menopausal-related symptoms or disorders when compared to an average normal menopausal woman following a conventional nutritional regimen. 
 Example 3 A soft gelatin supplement in accordance with the compositions of Examples 1 and 2 above, may be prepared, by first combining mineral oil and soybean oil in a first vessel and blending it to form a uniform oil mixture, heating the oil mixture to 45 degrees Celsius, and then adding propylene glycol. In a second vessel preheated to 70 degrees Celsius, yellow beeswax and soybean oil are added and blended until a uniform wax mixture is formed. The wax mixture is cooled to 35 degrees Celsius and then added to the oil mixture. To this combined oil and wax mixture, folic acid, vitamin B 6 , iron, magnesium, and calcium are then added and blended together to form a uniform biologically active mixture. The mixture is then cooled to 30 degrees Celsius to form a viscous biologically active core composition, after which time the composition is ready for encapsulation in a soft gelatin shell. A soft gelatin shell is prepared by heating purified water in a suitable vessel and then adding gelatin. This water gelatin mixture is mixed until the gelatin is fully dissolved, and then glycerin, preservatives, one or more flavors, and one or more colorants are added. This gelatin mixture is blended well and cooled. The shells are then filled with the core composition and formed in accordance with soft gelatin techniques commonly used and well known to persons of skill in the art. 
 Example 4 The following compositions are for administration to premenopausal women and menopausal women in accordance with the regimen indicated below: 3 Regimen Component Dose First Morning Calcium Carbonate 350 mg Tablet (orange): B Complex 55 mg Second Morning Calcium Carbonate 350 mg Tablet (white): Vitamin A 3,000 IU Vitamin C 100 IU Vitamin D 400 IU Selenium 65 mcg Zinc 15 mg Copper 2 mg Evening Tablet Calcium Carbonate 350 mg B Complex 110 mg Vitamin A 2,000 IU Folic Acid 1 mg Evening Capsule Vitamin E 400 IU DHA 50 mg Linolenic Acid 25 mg Linoleic Acid 25 mg Calcium Carbonate 150 mg Evening Tablet Alendronate 10 mg It would be anticipated that upon following the above regimen, an average normal menopausal woman would be expected to have reduced incidence of nutritional deficiency and reduced menopausal-related symptoms or disorders when compared to an average normal menopausal woman following a conventional nutritional regimen. 
 Example 5 The following compositions are for administration to premenopausal women and menopausal women in accordance with the regimen indicated below: 4 Regimen Component Dose First Morning Calcium Carbonate 350 mg Tablet (orange): B Complex 55 mg Second Morning Calcium Carbonate 350 mg Tablet (white): Vitamin A 3,000 IU Vitamin C 100 IU Vitamin D 400 IU Selenium 65 mcg Zinc 15 mg Copper 2 mg Evening Tablet Calcium Carbonate 350 mg B Complex 110 mg Vitamin A 2,000 IU Folic Acid 1 mg Evening Capsule Vitamin E 400 IU DHA 50 mg Linolenic Acid 25 mg Linoleic Acid 25 mg Calcium Carbonate 150 mg Evening Tablet PREMPRO ™ conjugated estrogens 2.5 mg progesterone 2.5 mg It would be anticipated that upon following the above regimen, an average normal menopausal woman would be expected to have reduced incidence of nutritional deficiency and reduced menopausal-related symptoms or disorders when compared to an average normal menopausal woman following a conventional nutritional regimen. The inventive subject matter being thus described, it will be apparent that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the inventive subject matter, and all such modifications are intended to be within the scope of the appended claims.